Defense Group

Defence Therapeutics is a Canadian clinical-stage biotechnology company specializing in precision intracellular drug delivery for oncology and infectious diseases. The company's proprietary Accum® platform technology is designed to enhance the delivery of biological molecules, such as antibody-drug conjugates (ADCs) and vaccines, by facilitating their escape from endosomes into the cytoplasm or nucleus. Its lead program, AccuTOX, is a small molecule/peptide-based anti-cancer therapy currently in clinical development for solid tumors. Additionally, the company is advancing a diverse pipeline that includes the AccuVAC vaccine platform and the ARM-X cell-based vaccine technology, aiming to transform existing and next-generation biologics into more effective first-line treatments.